Encourage People with Substance Use Disorders to Get Vaccinated Against COVID-19
Substance use disorders can increase the risk for becoming severely ill from COVID-19, making vaccinations vital.
Nora's Blog
New NIDA Research Reveals the Power of Social Reinforcers
|
Medication is a crucial part of treating addiction—but by itself, a pill or an injection may not be sufficient. Social support has long been known to be an important factor...
6 Comments
Recent Research Sheds New Light on Why Nicotine is So Addictive
|
Nicotine does not produce the kind of euphoria or impairment that many other drugs like opioids and marijuana do. People do not get high from smoking cigarettes or vaping. Yet...
The HEALing Communities Study: Using Science to Address the Opioid Crisis
|
The public health emergency of opioid misuse and addiction affects millions of Americans and requires innovative scientific solutions. Today, during “National Prescription Opioid and Heroin Awareness Week,” we are sharing...
How Can We Better Support Physicians in Addressing the Opioid Crisis?
|
Ample evidence shows methadone and buprenorphine reduce overdose deaths, prevent the spread of diseases like HIV, and enable people to take back their lives, but there are restrictions on who...
NIH Partners with the Dental Community to Help Curb the Opioid Crisis
|
Reducing healthcare’s reliance on potentially addictive opioid pain relievers has been one of the pillars of federal efforts to reverse the opioid crisis.
FDA Approves First Drug Derived from Marijuana
|
This week, the Food and Drug Administration (FDA) approved Epidiolex (cannabidiol, or CBD), a medication extracted from marijuana, for the treatment of two severe pediatric seizure disorders.
An Ambitious Research Plan to Help Solve the Opioid Crisis
|
In spring 2018, Congress added an additional $500 million to the NIH budget to invest in science to find solutions to the opioid crisis. The funding that NIDA is receiving...
NIDA-Supported Science Leads to First FDA-Approved Medication for Opioid Withdrawal
|
This week, the Food and Drug Administration (FDA) approved lofexidine, the first medication targeted specifically to treat the physical symptoms associated with opioid withdrawal.
Million-Participant NIH Study Could Yield Important Insights into Addiction and Pain
|
New data-gathering and analytic capabilities are enabling the kinds of massive, long-term studies needed to investigate genetic, environmental, and lifestyle factors that contribute to disease.
|
Today, a new analysis in JAMA by epidemiologists at NIDA and the Substance Abuse and Mental Health Services Administration reveals the scope of the crisis, and the rapidity with which...